Eli Lilly (opens in new tab)'s once-daily weight-loss pill Foundayo (orforglipron) reduced the severity of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight in two year-long phase 3 trials, according to results published in JAMA (opens in new tab) and presented Monday at the American Heart Association (opens in new tab)'s Scientific Sessions 2026 in Chicago. Lilly funded the studies.
The ATTAIN-OSA program enrolled 712 people in two trials: 363 who couldn't or wouldn't use positive airway pressure (PAP) machines such as CPAP, and 349 who kept using PAP during the study, CNBC (opens in new tab) reported. In the JAMA (opens in new tab) research summary, the number of breathing interruptions per hour of sleep, known as the apnea-hypopnea index, fell by 17.8 with orforglipron versus 4.5 with placebo in the first trial, and by 17.3 versus 5.3 in the second. Lilly's release gives larger reductions of 21.1 versus 4.3 events per hour without PAP and 18.3 versus 5.5 with PAP, and says 31.5% of patients not using PAP reached remission or mild disease.
Participants lost about 11% of their body weight, according to Lilly, and blood pressure fell by about seven points after a year, presenting author Dr. Vaishnavi Kundel of the Icahn School of Medicine at Mount Sinai said in the AHA release. Researchers said weight loss likely contributed to the improvements and that the drug is not meant to replace CPAP. "A convenient daily pill may help expand access to treatment for sleep apnea, and it could potentially be used with CPAP or other therapies," Kundel said.
Side effects were mostly gastrointestinal, including nausea, diarrhea, constipation and vomiting. About 12% of people taking the pill without PAP stopped because of side effects, compared with 3.8% on placebo, CNBC (opens in new tab) reported. Lilly's injectable Zepbound became the first drug approved for sleep apnea in December 2024. Foundayo, on the U.S. market since April for weight loss, is not yet approved for sleep apnea, and Lilly says it will submit the data to the FDA by year's end.